ImmunityBio (IBRX) said Wednesday it has entered into a collaboration and supply agreement with BeiGene to conduct a phase 3 clinical trial combining BeiGene's tislelizumab and ImmunityBio's Anktiva as a potential therapy for the advanced or metastatic non-small cell lung cancer in patients who have acquired resistance to immune checkpoint inhibitors therapy.
Financial terms of the collaboration weren't disclosed.
ImmunityBio said it will conduct the confirmatory phase 3 trial across multiple sites and among 462 participants.
The primary endpoint of the study is overall survival, while secondary endpoints include disease control rate, progression-free survival, objective response rate, and safety, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.